References
- Vos T, Abajobir AA, Abbafati C, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211–1259.
- Turner DP, Golding AN, Houle TT. Using a graphical risk tool to examine willingness to take migraine prophylactic medications. Pain. 2016;157(10):2226.
- Al-Hashel JY, Ahmed SF, Alshawaf FJ, et al. Use of traditional medicine for primary headache disorders in Kuwait. J Headache Pain [Internet]. 2018;19:118. [cited 2020 Feb 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30514208.
- Ashina M, Hansen JM, Do TP, et al. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol [Internet]. 2019;18:795–804. [cited 2019 Jun 2]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1474442219301851.
- Blau JN, Cumings JN. Method of precipitating and preventing some migraine attacks. Br Med J [Internet]. 1966;2:1242–1243. [cited 2018 Nov 12]. Available from: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1944776&blobtype=pdf.
- Hockaday JM, Williamson DH, Whitty CWM. Blood-glucose levels and fatty-acid metabolism in migraine related to fasting. Lancet. 1971;297:1153–1156.
- Pavlovic JM, Buse DC, Sollars CM, et al. Trigger factors and premonitory features of migraine attacks: summary of studies. Headache J Head Face Pain. 2014;54:1670–1679.
- Peroutka SJ. What turns on a migraine? A systematic review of migraine precipitating factors. Curr Pain Headache Rep. 2014;18:454.
- Aytaç B, Ö C, Alioğlu B, et al. Decreased antioxidant status in migraine patients with brain white matter hyperintensities. Neurol Sci. 2014;35:1925–1929.
- Alp R, Selek S, Alp SI, et al. Oxidative and antioxidative balance in patients of migraine. Eur Rev Med Pharmacol Sci. 2010;14:877–882.
- Siva ZO, Uluduz D, Keskin FE, et al. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine. Cephalalgia. 2018;38(11):1773–1781.
- Sacco S, Altobelli E, Ornello R, et al. Insulin resistance in migraineurs: results from a case-control study. Cephalalgia. 2014;34:349–356.
- Sangiorgi S, Mochi M, Riva R, et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia. 1994;14:21–23.
- Montagna P, Cortelli P, Monari L, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology [Internet]. 1994;44:666–669. [cited 2017 Dec 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8164822.
- Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology [Internet]. 1992;42:1209–1214. [cited 2018 Feb 23]. Available from]. http://www.ncbi.nlm.nih.gov/pubmed/1603349.
- Reyngoudt H, Paemeleire K, Descamps B, et al. 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia. 2011;31:1243–1253.
- Lodi R, Iotti S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull [Internet]. 2001;54:437–441. [cited 2018 Feb 27]. Available from; http://www.ncbi.nlm.nih.gov/pubmed/11306197.
- Zaki E, Freilinger T, Klopstock T, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia. 2009;29:719–728.
- Eising E, De Vries B, Ferrari MD, et al. Pearls and pitfalls in genetic studies of migraine. Cephalalgia. 2013;33(8):614–625.
- Eising E, Huisman SMH, Mahfouz A, et al. Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen human brain atlas. Hum Genet [Internet]. 2016;135:425–439. [cited 2016 Jun 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26899160.
- Gantenbein AR, Sandor PS, Fritschy J, et al. Sensory information processing may be neuroenergetically more demanding in migraine patients. Neuroreport [Internet]. 2013;24:202–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23381352.
- Lisicki M, D’Ostilio K, Coppola G, et al. Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials. J Headache Pain [Internet]. 2018;19:49. [cited 2018 Jul 6]. Available from: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-018-0877-8.
- Kilic K, Karatas H, Dönmez-Demir B, et al. Inadequate brain glycogen or sleep increases spreading depression susceptibility. Ann Neurol [Internet]. 2018;83:61–73. [cited 2018 Apr 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29244233.
- Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science [Internet]. 2013;339:1092–1095. [cited 2016 Jun 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23449592.
- Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004;11:475–477.
- Condò M, Posar A, Arbizzani A, et al. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10:361–365.
- Bruijn J, Duivenvoorden H, Passchier J, et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia An Int J Headache. 2010;30:1426–1434.
- Rahimdel A, Zeinali A, Yazdian-Anari P, et al. Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Physician. 2015;7(6):1344.
- Hershey AD, Powers SW, Vockell A-LB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47:73–80.
- Slater SK, Nelson TD, Kabbouche MA, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31:897–905.
- Shoeibi A, Olfati N, Soltani Sabi M, et al. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg. 2017;117:103–109.
- Dahri M, Hashemilar M, Asghari-Jafarabadi M, et al. Efficacy of coenzyme Q10 for the prevention of migraine in women: A randomized, double-blind, placebo-controlled study. Eur J Integr Med. 2017;16:8–14.
- Cavestro C, Bedogni G, Molinari F, et al. Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: a 6-month exploratory study. J Med Food. 2018;21:269–273.
- Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298–301.
- Karimi N, Razian A, Heidari M. The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study. Acta Neurol Belg. 2019;1–7.
- Menon S, Lea RA, Ingle S, et al. Effects of dietary folate intake on migraine disability and frequency. Headache. 2015;55:301–309.
- Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia. 1994;14(5):328–329.
- Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology [Internet]. 1998;50:466–470. [cited 2016 Jun 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9484373.
- Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: A systematic review. J Clin Pharm Ther. 2017;42:394–403.
- Di Lorenzo C, Pierelli F, Coppola G, et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology [Internet]. 2009;72:1588–1594. [cited 2018 Nov 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19414726.
- Lea R, Colson N, Quinlan S, et al. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics. 2009;19:422–428.
- Menon S, Lea RA, Roy B, et al. Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet Genomics [Internet]. 2012;22:741–749. [cited 2019 Jul 16]. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01213011-201210000-00005.
- Menon S, Nasir B, Avgan N, et al. The effect of 1 mg folic acid supplementation on clinical outcomes in female migraine with aura patients. J Headache Pain [Internet]. 2016;17:60. [cited 2019 Jul 16]. Available from: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-016-0652-7.
- Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22(2):137–141.
- Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713–715.
- Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, et al. Oral coenzyme Q10 supplementation in patients with migraine: effects on clinical features and inflammatory markers. Nutr Neurosci [Internet]. 2019;22:607–615. [cited 2020 Feb 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29298622.
- Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo31P-MRS in a patient with mitochondrial cytopathy. J Neurol. 1995;242(7):472–477.
- Magis D, Ambrosini A, Sándor P, et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache. 2007;47:52–57.
- Cavestro C, Bedogni G, Molinari F, et al. Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: a 6-month exploratory study. J Med Food [Internet]. 2017;21:jmf.2017.0068. Available from: http://online.liebertpub.com/doi/10.1089/jmf.2017.0068.
- Di Lorenzo C, Coppola G. Obesity, diet and nutraceuticals. J Headache Pain [Internet]. 2015;16:1. [cited 2020 Feb 8]. Available from: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/1129-2377-16-S1-A28.
- Ali AM, Awad TG, Al-Adl NM. Efficacy of combined topiramate/thioctic acid therapy in migraine prophylaxis. Saudi Pharm J. 2010;18:239–243.
- Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, et al. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012;150:42–48.
- Hagen K, Brenner E, Linde M, et al. Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Cephalalgia [Internet]. 2015;35:987–995. [cited 2019 Jul 16]. Available from: http://journals.sagepub.com/doi/10.1177/0333102414566817.
- Hajihashemi P, Askari G, Khorvash F, et al. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia [Internet]. 2019;39. [cited 2019 Jul 16]. Available from:: https://journals.sagepub.com/doi/pdf/10.1177/0333102418821661.
- Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation [Internet]. Cell Metab. Elsevier; Dec 7, 2011;14(6):724–738. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22152301.
- Barbanti P, Fofi L, Aurilia C, et al. Ketogenic diet in migraine: rationale, findings and perspectives. Neurol Sci. 2017;38:111–115.
- Boison D. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017;30(2):187.
- Gross EC, Klement RJ, Schoenen J, et al. Potential protective mechanisms of ketone bodies in migraine prevention. [Internet]. Nutrients. Multidisciplinary Digital Publishing Institute. 2019; p. 811. [cited 2019 Jun 1]. Available from: https://www.mdpi.com/2072-6643/11/4/811.
- TG SCHNABEL. An experience with a ketogenic dietary in migraine. Ann Int Med [Internet]. 2:341. [cited 2019 Feb 25]. DOI: 10.7326/0003-4819-2-4-341
- Strahlman RS. Can ketosis help migraine sufferers? A case report [5]. [Internet]. Headache. 2006; p. 182. [cited 2016 Aug 15]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16412174.
- Di Lorenzo C, Currà A, Sirianni G, et al. Diet transiently improves migraine in two twin sisters: possible role of ketogenesis? Funct Neurol. 2013:28(4):305–308.
- Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. 22:170–177. cited 2016 Aug 15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25156013
- Di Lorenzo C, Coppola G, Bracaglia M, et al. Cortical functional correlates of responsiveness to short-lasting preventive intervention with ketogenic diet in migraine: a multimodal evoked potentials study. J Headache Pain [Internet]. 2016;17:58. [cited 2016 Aug 15]. Available from. http://www.ncbi.nlm.nih.gov/pubmed/27245682.
- Di LC, Coppola G, Bracaglia M, et al. A ketogenic diet normalizes interictal cortical but not subcortical responsivity in migraineurs. [ cited 2019 Jul 16]. Available from: https://doi.org/10.1186/s12883-019-1351-1.
- Di Lorenzo C, Pinto A, Ienca R, et al. A randomized double-blind, cross-over trial of very low-calorie diet in overweight migraine patients: A possible role for ketones?. Nutrients. 2019;11(8):1742.
- Gross E, Putananickal N, Orsini A-L, et al. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial. Trials [Internet]. 2019;20:61. [cited 2019 Feb 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30654835.
- Adanyeguh IM, Rinaldi D, Henry P-G, et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology [Internet]. 2015;84:490–495. [cited 2019 Jun 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25568297.
- Schoenen J. A pilot trial of triheptanoin for the preventive treatment of migraine - final clinical report on file - ClinicalTrials.gov. [Internet]. [cited 2019 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02784847.
- Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract. 2005;59(8):961–968.
- Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28(9):1225–1237.
- Goadsby PJ, Dodick DW, Trugman JM, et al. Efficacy, safety, and tolerability of orally administered atogepant for the prevention of episodic migraine: results from a phase 2B/3 study. Cephalalgia [Internet]. 2018;38:123–155. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01653148/full%0Ahttps://www.cochranelibrary.com/central/doi/10.1002/central/CN-01653279/full.
- Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015.
- Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med [Internet]. 2017;377:2123–2132. [cited 2019 Jun 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29171821.
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology [Internet]. 2012;78:1337–1345. Available from: http://www.neurology.org/lookup/doi/10.1212/WNL.0b013e3182535d20.1
- Leroux E, Dilli E, Worthington I, et al. Canadian headache society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2015;14(11):1081–1090.
- Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - Revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981.
- Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain [Internet]. 2018 Dec 21;19:17. [cited 2018 Apr 16]. Available from: https://thejournalofheadacheandpain.springeropen.com/articles/10.1186/s10194-018-0846-2.
- Gross EC, Lisicki M, Fischer D, et al. The metabolic face of migraine — from pathophysiology to treatment. Nat Rev Neurol. 2019;15(11):627–643.
- Search of: metabolism OR Riboflavin OR Coenzyme-Q OR Ketones OR Lipoic acid | MIgraine disorders - List results - ClinicalTrials.gov. [Internet]. [cited 2019 Feb 25]. Available from: https://clinicaltrials.gov/ct2/results?cond=Migraine+Disorders&term=metabolism+OR+Riboflavin+OR+Coenzyme-Q+OR+Ketones+OR+Lipoic+acid&cntry=&state=&city=&dist=
- KAWAMURA, Masahito; RUSKIN, David N.; MASINO, Susan A. Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels. Journal of Neuroscience, 2010, vol. 30, no 11, p. 3886–3895.